Gonadorelin vs PT-141

Synthetic GnRH that binds pituitary GnRH receptors; pulsatile dosing stimulates LH/FSH release; used to maintain HPG axis during TRT

Gonadorelin is the synthetic form of endogenous gonadotropin-releasing hormone (GnRH), the hypothalamic decapeptide that drives the pulsatile reproductive axis by stimulating pituitary release of LH and FSH. When delivered in a pulsatile pattern mimicking the hypothalamic pulse generator, gonadorelin effectively restores normal gonadotropin secretion and reproductive function in individuals with hypothalamic hypogonadism. Peer-reviewed clinical studies demonstrate efficacy of pulsatile gonadorelin pump therapy for testosterone restoration in men with congenital hypogonadotropic hypogonadism, as well as for ovulation induction in women with hypothalamic amenorrhea. Gonadorelin is a prescription peptide requiring specialist oversight; continuous rather than pulsatile administration produces paradoxical gonadotropin suppression, making context of use clinically critical. Gonadorelin dosage in TRT support contexts: in men on testosterone replacement therapy, gonadorelin is commonly used off-label to maintain testicular function and endogenous testosterone production capacity. Subcutaneous doses of 100 mcg administered twice weekly are frequently cited in TRT clinical protocols for this purpose — injected at a pulsatile rather than continuous delivery pattern to preserve LH/FSH signaling. This application requires physician supervision due to the dose-timing sensitivity; the paradoxical suppression from continuous dosing is a clinically important consideration that distinguishes gonadorelin from simpler TRT adjuncts. Gonadorelin vs hCG: both are used in men's health contexts to maintain testicular function alongside testosterone therapy, but they act at different levels of the HPG axis. hCG acts directly at the Leydig cell LH receptor to drive testicular testosterone production, bypassing the pituitary. Gonadorelin acts at the pituitary to stimulate endogenous LH and FSH release — preserving the full hypothalamic-pituitary axis rather than just the downstream testosterone signal. The clinical distinction matters for fertility: gonadorelin preserves FSH stimulation of sperm production alongside testosterone, while hCG stimulates testosterone without independently driving FSH. Telehealth hormone therapy providers offering gonadorelin are listed in the PeptideBase directory.

PT-141 is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly within the hypothalamus. Unlike peripherally acting agents, it modulates sexual arousal at the CNS level via dopaminergic pathways, independent of vascular mechanisms. Bremelanotide received FDA approval as Vyleesi for hypoactive sexual desire disorder in premenopausal women.

PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist and the first centrally acting peptide approved by the FDA for a sexual dysfunction indication — marketed as Vyleesi (Palatin Technologies / AMAG Pharmaceuticals) for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike phosphodiesterase-5 inhibitors such as sildenafil, which act peripherally through vascular smooth muscle relaxation, PT-141 acts centrally via melanocortin MC3R and MC4R receptors in the hypothalamus to modulate sexual motivation and arousal pathways — a mechanistically distinct approach that is effective regardless of vascular status. Pivotal Phase 3 RCTs in premenopausal women with HSDD demonstrated statistically significant improvements in satisfying sexual events and desire scores versus placebo, establishing the clinical evidence base for FDA approval in 2019. PT-141 dosage: the FDA-approved dose is 1.75mg administered as a single subcutaneous injection in the abdomen using an auto-injector device, approximately 45 minutes before anticipated sexual activity; it should not be used more than once per 24 hours or more than 8 times per month per prescribing guidance. Compounded PT-141 — available through licensed compounding pharmacies — is commonly prepared in 10mg vials for research contexts; typical compounded doses range from 1–2mg per use. PT-141 nasal spray formulations have been investigated as an alternative delivery route, though the approved form is subcutaneous injection. PT-141 for men: while FDA approval is limited to premenopausal women with HSDD, PT-141 is used off-label in men for sexual dysfunction, including cases where PDE5 inhibitors are insufficient or contraindicated; the central mechanism of action is not sex-specific. Side effects: the most common adverse effect is nausea (reported in approximately 40% of subjects in pivotal trials), followed by flushing, headache, and transient hyperpigmentation with repeated use. A transient increase in blood pressure is observed in the first hour post-injection; PT-141 is contraindicated in patients with uncontrolled hypertension or cardiovascular disease. PT-141 (Vyleesi) is FDA-approved and requires a prescription; compounding pharmacy access also requires a prescription. Providers offering PT-141 consultations — including telehealth platforms — can be found in the PeptideBase directory.